Napp: Nyxoid described as “a new option” on website beyond 12 months (AUTH/3306/2/20)

📅 2020 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/3306/2/20
CompanyNapp Pharmaceuticals Limited
ProductNyxoid (intranasal naloxone spray)
IssueUse of the word “new” (“a new option”) beyond 12 months of general availability
MaterialCorporate website page (napp.co.uk/overdose-therapy), downloaded 6 February 2020
ComplainantConcerned UK health professional
Applicable Code year2019
Breach clausesClause 7.11
Panel decisionBreach of Clause 7.11 ruled
Company responseApologised; said it was an oversight; removed the section and updated the page; acknowledged breach
Complaint received6 February 2020
Case completed9 April 2020
AppealNo appeal
SanctionsUndertaking received

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • A UK health professional complained about a Napp corporate webpage (downloaded 6 February 2020) describing Nyxoid (intranasal naloxone spray) as “a new option” for treating overdose.
  • The complainant said Nyxoid had been on the market for more than 12 months.
  • The PMCPA asked Napp to consider Clause 7.11 (use of the word “new”).
  • Napp said the page was general product information on its corporate website and apologised, stating it was an oversight.
  • After the complaint, Napp removed the relevant section and made changes to align with Clause 7.11.
⚖️

Outcome

  • Breach ruled: Yes.
  • The Panel ruled that describing Nyxoid as “a new option” on 6 February 2020 breached the Code because the medicine had been generally available for more than 12 months.
  • Napp acknowledged the breach.
  • No appeal.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training